SCHEMBL18013034

SCHEMBL18013034

Oc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OCCCN1CCC(OC(F)F)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 15/20 0.59
KDR P35968 5/20 0.55
ERBB2 P04626 2/20 0.54
AURKA O14965 1/20 0.48
FBP1 P09467 1/20 0.48
BRAF P15056 2/20 0.48
SRC P12931 2/20 0.48
CIT O14578 1/20 0.48
GAK O14976 1/20 0.48
EPHB6 O15197 1/20 0.48
ABCC4 O15439 1/20 0.48
DAPK3 O43293 1/20 0.48
RIPK2 O43353 1/20 0.48
NR1I2 O75469 1/20 0.48
RPS6KA4 O75676 1/20 0.48
STK17B O94768 1/20 0.48
STK10 O94804 1/20 0.48
PRKD3 O94806 1/20 0.48
ABCB11 O95342 1/20 0.48
MAP4K4 O95819 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18013037 0.90 EGFR (0.63) EGFRKDRERBB2BRAFSRC
SCHEMBL18012082 0.90 EGFR (0.64) EGFRKDRERBB2FBP1BRAF
SCHEMBL18013035 0.85 EGFR (0.63) EGFRKDRERBB2BRAFSRC
SCHEMBL18013062 0.85 EGFR (0.63) EGFRKDRERBB2BRAFSRC
SCHEMBL18013036 0.85 ERBB2 (0.57) EGFRKDRERBB2RETFLT4
SCHEMBL18012092 0.82 EGFR (0.69) EGFRKDRERBB2BRAFSRC
SCHEMBL19885294 0.81 EGFR (0.65) EGFRKDRERBB2BRAFSRC
SCHEMBL18013033 0.81 EGFR (0.69) EGFRKDRFBP1SRCABL1
SCHEMBL18012090 0.80 EGFR (0.78) EGFRKDRERBB2BRAFSRC
SCHEMBL19885293 0.78 EGFR (0.65) EGFRKDRERBB2BRAFSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016123706-A1 NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS TRILLIUM THERAPEUTICS INC. (CA) 2016-08-11 WO disclosed